

1 **Title:** Time trends, factors associated with, and reasons for COVID-19 vaccine hesitancy in a
2 massive online survey of US adults: January-May 2021

3 **Running Title:** COVID-19 vaccine hesitancy in US adults

4 **Authors and Affiliations:**

5 Wendy C King¹, Max Rubinstein^{2,3}, Alex Reinhart², Robin Mejia^{2*}

6 ¹ Department of Epidemiology, Graduate School of Public Health University of Pittsburgh,
7 Pittsburgh, PA, United States of America

8 ²Department of Statistics & Data Science, Carnegie Mellon University, Pittsburgh, PA, United
9 States of America

10 ³Heinz College, Carnegie Mellon University, Pittsburgh, PA, United States of America

11

12 *Corresponding author:

13 Email: rmejia@andrew.cmu.edu (RM)

14 **Word count:** 4038

15 **Abstract word count:** 352 words

16

17

18 **Abstract**

19 **Importance:** COVID-19 vaccine hesitancy has become a leading barrier to increasing the US
20 vaccination rate.

21 **Objective:** To evaluate time trends in COVID-19 vaccine intent during the US vaccine rollout,
22 and identify key factors related to and self-reported reasons for COVID-19 vaccine hesitancy in
23 May 2021.

24 **Design, participants and setting:** A COVID-19 survey was offered to US adult Facebook users in
25 several languages yielding 5,088,772 qualifying responses from January 6 to May 31, 2021. Data
26 was aggregated by month. Survey weights matched the sample to the age, gender, and state
27 profile of the US population.

28 **Exposure:** Demographics, geographic factors, political/COVID-19 environment, health status,
29 beliefs, and behaviors.

30 **Main outcome measures:** “If a vaccine to prevent COVID-19 were offered to you today, would
31 you choose to get vaccinated.” Hesitant was defined as responding probably or definitely would
32 not choose to get vaccinated (versus probably or definitely would, or already vaccinated).

33 **Results:** COVID-19 vaccine hesitancy decreased by one-third from 25.4% (95%CI, 25.3, 25.5) in
34 January to 16.6% (95% CI, 16.4, 16.7) in May, with relatively large decreases among participants
35 with Black, Pacific Islander or Hispanic race/ethnicity and \leq high school education. Independent
36 risk factors for vaccine hesitancy in May (N=525,644) included younger age, non-Asian race, < 4
37 year college degree, living in a more rural county, living in a county with higher Trump vote
38 share in the 2020 election, lack of worry about COVID-19, working outside the home, never

39 intentionally avoiding contact with others, and no past-year flu vaccine. Differences in hesitancy
40 by race/ethnicity varied by age (e.g., Black adults more hesitant than White adults <35 years
41 old, but less hesitant among adults ≥45 years old). Differences in hesitancy by age varied by
42 race/ethnicity. Almost half of vaccine hesitant respondents reported fear of side effects (49.2%
43 [95%CI, 48.7, 49.7]) and not trusting the COVID-19 vaccine (48.4% [95%CI, 48.0, 48.9]); over
44 one-third reported not trusting the government, not needing the vaccine, and waiting to see if
45 safe. Reasons differed by degree of vaccine intent and by race/ethnicity.

46 **Conclusion:** COVID-19 vaccine hesitancy varied by demographics, geography, beliefs, and
47 behaviors, indicating a need for a range of messaging and policy options to target high-
48 hesitancy groups.

49 **Introduction**

50 On December 11, 2020(1), the Federal Drug Administration (FDA) granted the first Emergency
51 Use Authorization of a COVID-19 vaccine in the United States (US) (2). By March 2021, 3 COVID-
52 19 vaccines had been authorized(3), and the president announced procurement of enough
53 doses for every adult to be vaccinated by the end of May 2021 (4). By May 2021, vaccine
54 eligibility was expanded to everyone covered under the FDA authorizations (initially ≥ 16 years
55 old, expanded to ≥ 12 years old on May 10 (5)), and efforts to increase vaccine access to
56 underserved populations were underway (6,7). However, COVID-19 vaccine hesitancy (i.e., a
57 refusal or reluctance to be vaccinated) slowed vaccination uptake (8). By July 2021, COVID-19
58 vaccine hesitancy, which appears to be a distinct phenomenon from general vaccine hesitancy
59 (9), was widely perceived by the public as prolonging the pandemic; on August 1, it was the
60 subject of a New York Times front-page story (10), and was center-stage to disease control
61 discussions as a fourth COVID-19 surge filled hospitals across parts of the US (11,12).

62 A longitudinal study of US adults (N=7,420) by Daly et al. reported an overall decrease in COVID-
63 19 vaccine hesitancy from 46.0% in October 2020 to 35.2% in March 2021. Throughout this
64 timeframe, younger versus older adults, and Black versus White adults, had greater COVID-19
65 vaccine hesitancy, however, trends suggested an increase in the age disparity and decrease in
66 the racial disparity in vaccine uptake (13). Understanding how COVID-19 vaccine hesitancy
67 prevalence continued to change up through the time of adult universal eligibility, overall and
68 among subgroups, as well as reasons for hesitancy at the time of universal eligibility is essential
69 for policy makers working to increase vaccination uptake.

70 Since April 2020, the Delphi Group at Carnegie Mellon University (CMU) has been conducting a
71 national online COVID-19 Trends and Impact Survey (CTIS) (14) in collaboration with a
72 consortium of universities and Facebook Data for Good (14). Among a massive sample of US
73 adults who completed the CTIS January-May, 2021, we report COVID-19 vaccine uptake and
74 intent by month, and evaluate time trends in vaccine hesitancy prevalence by race/ethnicity,
75 education, US region and political environment. For May, the prevalence of COVID-19 vaccine
76 hesitancy is reported by demographics, geographic factors, political/COVID-19 environment,
77 health status, beliefs and behaviors, and associations between each potential risk factor with
78 hesitancy is estimated with and without adjustment for potential confounders. Lastly, we
79 identify the most common reasons for COVID-19 vaccine hesitancy by level of COVID-19 vaccine
80 intent and race/ethnicity.

81 **Methods**

82 **Survey sampling and weighting**

83 Each month, January-May, 2021, the CTIS was offered to a random sample, stratified by
84 geographic region, of ≈ 100 million US residents from the Facebook Active User Base who used
85 one of the supported languages (English [American and British], Spanish [Spain and Latin
86 American], French, Brazilian Portuguese, Vietnamese, and simplified Chinese). The offer to
87 participate was shown with a survey link at the top of users' Facebook News Feed, from once a
88 month to once every six months, depending on their geographic strata, with the intent to yield
89 ≈ 1.1 million responders monthly, to allow for evaluation of local trends. When individuals
90 clicked through the link, an anonymized unique identifier was generated. CMU returned the

91 unique IDs to Facebook, which created weights that account for the sampling design and non-
92 response; these weights were then post-stratified to match the US general population by age,
93 gender, and state (14,15). The design ensured CMU researchers did not see user names or
94 profile information, and Facebook did not see survey microdata. The CMU Institutional Review
95 Board approved the survey protocol and instrument (STUDY2020_00000162).

96 **Study sample**

97 The same version of the vaccine uptake and intent questions were offered to all potential CTIS
98 respondents from January 6 to May, 19, 2021, and to approximately 15% of potential
99 respondents from May 20-31. This study is limited to responses from these offers (5,485,862 of
100 476,648,117; response rate 1.2%). Respondents who did not complete the questions on vaccine
101 uptake and intent (N=365,426), or reported gender as, “prefer to self-describe,” (N=31,664),
102 were excluded, resulting in a sample of 5,088,772; self-described gender (selected by <1% of
103 responders) had a high prevalence of discriminatory descriptions and uncommon responses
104 (e.g., Hispanic ethnicity [41.4%], the oldest age group [23.2% ≥75 years] and highest education
105 level [28.1% Doctorate]), suggesting the survey was not completed in good faith. A sensitivity
106 analysis was conducted including all gender responses.

107 **Measures**

108 The survey questions and response sets utilized in this report are provided in supporting
109 information, **sAppendix**. Vaccination questions were adapted from CDC-sponsored questions
110 developed for two household panel surveys (16) and shared with us prior to launch. The answer
111 set for reasons for vaccine hesitancy was also expanded through a review of media reports and

112 brainstorming sessions among survey methodologists. We categorized participants as vaccine
113 hesitant if they answered that they probably or definitely would not choose to get vaccinated,
114 “if a vaccine to prevent COVID-19 were offered to you today,” (versus probably or definitely
115 would choose to get vaccinated or were already vaccinated). Those who had already received a
116 COVID-19 vaccine were coded as not hesitant to ensure a consistent study population, as access
117 to vaccinations varied by state and month in the studied timeframe.

118 The question on gender was developed for this survey; other demographic questions (age, race,
119 ethnicity, education, employment status) were adapted from existing surveys: race and
120 ethnicity from the 2020 Census (17), age categories match the 10-year blocks reported by the
121 American Community Survey (ACS) (18), and education categories were adapted from ACS (19).
122 Participants who reported Hispanic ethnicity were categorized by ethnicity. Non-Hispanic
123 participants were categorized by their race; non-Hispanic participants who reported more than
124 one race were categorized as multi-racial. Participants who did not select one of the named
125 races were categorized as missing. The “less than high school” and “high school graduate or
126 equivalent” categories were combined as “≤high school.” Likewise, “some college” and “2 year
127 degree” were combined as “some college.”

128 County-level variables were created using participants’ reported ZIP codes: US region (i.e.,
129 Census Bureau statistical region (20), dividing West into Mountain and Pacific, as vaccination
130 rates differed in these subregions (21)); urban-rural level of metropolitan statistical area
131 classification (22); and several political/COVID-19 environment indicators: quartile of county
132 COVID-19 death rate in the previous month (April 2021) (23), quartile of county Trump vote
133 share in the 2020 presidential election (calculated as percent voted for Trump minus percent

134 voted for Biden out of total votes within a county; not available for Alaska) (24), and state
135 governor's political party (not available for US territories) (25).

136 Questions related to health status, beliefs and behaviors included ever having tested positive
137 for COVID-19, ever diagnosed with specific health conditions (asthma, autoimmune disorder,
138 cancer, chronic obstructive pulmonary disease, diabetes type 1, diabetes type 2, heart disease,
139 high blood pressure, kidney disease, and weakened/compromised immune system), the extent
140 of worry about self or family becoming seriously ill from COVID-19, living with someone age 65
141 years or older, past-year flu vaccination, and the extent of intentionally avoiding contact with
142 others. Participants were categorized as having no health conditions or at least one health
143 condition. Additionally, participants were categorized as having high blood pressure only, each
144 of the other health conditions with or without high blood pressure, or "multiple conditions,"
145 defined as at least two conditions excluding high blood pressure, which was relatively common
146 and has limited support as a risk-factor for COVID-19 (26).

147 **Statistical analysis**

148 Data was aggregated by month to evaluate time trends in COVID-19 vaccine uptake and intent.
149 There may have been repeat respondents across months; however, respondents could not be
150 linked longitudinally, so data was treated as repeat cross-sectional surveys. All estimates were
151 generated using survey weights (15). We calculated percentages of COVID-19 vaccine intent or
152 hesitancy by month, as well as first-last month differences, for the full sample, and by
153 race/ethnicity, education, US region, and county Trump support. We limited the race/ethnicity

154 comparison to adults 18-34 years due to an interaction between race/ethnicity and age
155 (reported below with May data).

156 May 2021 data was used to assess how demographics, geographic factors, political/COVID-19
157 environment, health status, beliefs and behaviors related to COVID-19 vaccine hesitancy.
158 Specifically, we calculated percentages of COVID-19 vaccine hesitancy by all covariates and
159 used a series of weighted Poisson regression models with robust error variance to estimate the
160 risk ratios (RR) for vaccine hesitancy for each variable (27,28). Adjusted risk ratios (aRR) were
161 estimated from a single Poisson regression model including all covariates and an interaction
162 term for age group and race/ethnicity. To enable model fitting with an interaction term for age
163 and race, where age data was missing but race/ethnicity was available, race/ethnicity was
164 recoded to missing in the May sample. This affected 70 Hispanics, 262 Whites, 46 Blacks, 13
165 Asians, 15 Native Americans, 1 Pacific Islanders, and 30 multi-racial respondents (0.08% of our
166 sample). In a second multivariable model, a simplified health conditions variable (none, at least
167 one, described above) was replaced with the version specifying specific conditions to estimate
168 aRR by health condition. We calculated percentages of participants with each reason for
169 hesitancy by 3 levels of vaccine intent (definitely no, probably no, and probably yes), and by
170 race/ethnicity among hesitant participants.

171 For explanatory variables, “missing” was treated as a response category in the analyses. For all
172 parameters, 95% confidence intervals (CI) were calculated using robust standard errors (29).
173 Analyses were conducted in R (Version 4.0.2, R Core Team, Vienna, Austria).

174 **Results**

175 Study flow overall and by month is provided in supporting information, **sTable 1**. The January,
176 February, March, April and May samples had 1,195,650; 1,142,195; 1,209,536; 1,015,747; and
177 525,644 participants, respectively.

178 **Participant characteristics**

179 Excluding missing responses, weighted May participants had a median age range of 55-64
180 years; 45.7% identified as male, 53.2% female, 1.1% nonbinary; 16.4% were Hispanic, 69.1 %
181 White, 6.5% Black, 3.6% Asian, 0.8% Native American, 0.24% Pacific Islander, and 3.3% were
182 multi-racial; 22.5% had \leq high school education; 41.0% \geq four-year college degree. Over half
183 (56.0%) worked for pay; 42.9% worked outside the home. Demographics were similar January
184 through April (**sTable2**).

185 **COVID-19 vaccine receipt and intent over time**

186 Hesitancy decreased each month, with a one-third decrease from 25.4% (95%CI 25.3,25.5) in
187 January to 16.6% (95% CI, 16.4,16.7) in May, 2021. There was a bigger decrease in percentage
188 points in the response “probably not” (-7.1%[95% CI -7.2, -6.9]) versus “definitely not” (-1.8%
189 [95% CI -1.9, -1.7]) (**Figure 1; sTable 3**).

190 Per **Figure 2**, from January to May the gap in percent hesitant between race/ethnicity groups
191 among younger adults (**panel A**) and education levels among all respondents (**panel B**)
192 decreased, with the biggest decreases among two of the three most hesitant race/ethnicity
193 groups (e.g., Black and Pacific Islander but not Native American) and the two most hesitant

194 education groups (\leq high school and some college education) in January. Hesitancy appeared
195 relatively constant among those with a professional degree (e.g. MD, JD) or Doctorate.
196 Decreases in percent hesitant over time were fairly similar across US regions (**panel C**), with a
197 slightly smaller decrease in the Mountain region and slightly larger decrease in the South. The
198 gap in percent hesitant by Trump vote share increased slightly from January to May, with the
199 highest quartile, which was the most hesitant group, having the smallest decrease (**panel D**).
200 Supporting data is provided in **sTable 4**.

201 **Factors related to COVID-19 vaccine hesitancy**

202 Hesitancy in May, 2021 is reported by participant demographics and geographic factors in **Table**
203 **1** (N=525,644). Although hesitancy was lower in females versus males (RR 0.79, 95% CI 0.78,
204 0.81), with adjustment for covariates (i.e., variables reported in **Tables 1 and 2**), female gender
205 was associated with higher hesitancy (aRR 1.12, 95%CI 1.10, 1.14). Non-binary adults had
206 similar hesitancy to males (RR 1.10, 95%CI, 0.97, 1.22; aRR 0.99, 95%CI 0.88, 1.10).

207 In general, younger age and non-Asian race (particularly multi-racial and Native American),
208 were related to greater hesitancy. However, an interaction was observed between age and
209 race/ethnicity categories (**Figure 3**). Differences in hesitancy by age were more pronounced in
210 Blacks and less pronounced in Asians and Whites. Differences in hesitancy by race/ethnicity
211 were more pronounced in younger adults and adults ≥ 75 years. Furthermore, for some
212 comparisons, the direction of the difference differed by age. For example, for Blacks versus
213 Whites, the RR of hesitancy was 1.31 (95%CI, 1.12, 1.51) in 18-24 year olds, versus 0.50 (95%CI,
214 0.34, 0.67) in ≥ 75 year olds. **sTables 5 and 6** provide RRs for age groups stratified by

215 race/ethnicity groups and vice versa, with and without adjustment for all covariates. Age and
216 race/ethnicity differences were generally attenuated in the full multivariable model, but still
217 present.

218 The association between hesitancy and education level followed a U-shaped curve with the
219 lowest hesitancy among those with a master's degree, followed by those with a 4 year college
220 degree, then a professional degree, and a doctorate. The highest hesitancy was among those
221 with \leq high school education or some college (RR=1.89 [95%CI 1.84, 1.94] and 1.67 [95%CI 1.62,
222 1.71], respectively, versus a 4 year college degree). Additional demographic risk factors for
223 hesitancy included working outside the home (RR=2.44 [95%CI 2.35, 2.53]) or not working for
224 pay (RR=1.50 [95% CI: 1.44, 1.55]) versus working at home; living in the South (RR=1.62 95%CI
225 1.56, 1.67]), Midwest (RR=1.51 [95%CI 1.47, 1.56]) or Mountain (RR=1.50 [95%CI 1.44, 1.57])
226 versus the Pacific US region; and in a less urban county (e.g., RR=2.36 [95 CI, 2.28, 2.44] for non-
227 core versus large central metro). Associations were attenuated with adjustment (**Table 1**).

228 COVID-19 vaccine hesitancy is reported by indicators of political/COVID-19 environment, health
229 status, and beliefs and behaviors in **Table 2**. Risk factors for hesitancy were living in a state with
230 Republican versus Democratic governor (RR=1.34 [95%CI 1.32, 1.36]), living in a county with
231 higher Trump support (e.g., RR=2.57 [95%CI 2.50, 2.65] for highest versus lowest quartile),
232 living in a county with a lower April COVID-19 death rate (e.g., RR=0.70 [95%CI 0.68, 0.73] for
233 highest versus lowest quartile), history of a positive COVID-19 test versus no history (RR=1.26
234 [95%CI 1.23, 1.29]), not having versus having a high-risk health condition (RR=1.41 [95%CI 1.38,
235 1.43]), less worry about self or immediate family becoming seriously ill from COVID-19 (e.g.,
236 RR=3.66 [3.58, 3.74] for not worried at all versus worried), not having versus having received a

237 past-year flu vaccine (RR=4.97 [95%CI 4.85, 5.08]), and not avoiding versus avoiding contact
238 with others (e.g., RR=3.96 [95%CI 3.84, 4.07] for none versus all of the time). Political affiliation
239 of state governor was excluded from the multivariable model due to collinearity with county
240 Trump support. Associations from the multivariable model were attenuated but in the same
241 direction, except for April 2021 COVID-19 death rate, which was not independently related to
242 hesitancy.

243 COVID-19 vaccine hesitancy by specific health conditions is provided in **sTable 7**. Compared to
244 participants reporting none of the queried high-risk health conditions, hesitancy was lower
245 among participants with each health condition category except weakened or compromised
246 immune system (RR 1.10, [95%CI 1.02, 1.19]; aRR 1.43 [95%CI 1.33, 1.52]).

247 A sensitivity analysis including participants selecting “prefer to self-describe” gender is provided
248 in **sTable 8** and **sTable 9**. Overall, results were similar; however, hesitancy prevalence was
249 higher for a few categories (e.g., age ≥ 75 years, Hispanic, and Doctorate) where mis-reporting
250 was suspected.

251 **Reasons for COVID-19 vaccine hesitancy**

252 Reasons for hesitancy by applicable levels of intent are reported in **Table 3**. Concern about side
253 effects was chosen most frequently at 49.2% (95%CI, 48.7, 49.7) among hesitant participants,
254 and was similarly common across intent levels. In contrast, among adults who would “definitely
255 not” choose to be vaccinated, not trusting the COVID-19 vaccine and not trusting the
256 government were reported most frequently (59.2% [95%CI, 58.6, 59.8] and 51.2% [95%CI, 50.6,
257 51.7], respectively), double the prevalence seen among those who would “probably not” get

258 vaccinated and almost quadruple that of adults who “yes, probably” would. Conversely, 52.3%
259 (95%CI, 51.5, 53.1) of the “probably not” group said they would wait to see if it was safe, versus
260 only 24.3% (95%CI, 23.8, 24.8) of the “definitely not” group. Compared to most reasons for
261 vaccine hesitancy, not liking vaccines in general was chosen less frequently across all intent
262 levels (7.6% in “probably yes” to 17.6% in “definitely not”).

263 Reasons for COVID-19 vaccine hesitancy among hesitant US adults by race/ethnicity are
264 provided in **sTable 10**. Concern about side effects, followed by not trusting the COVID-19
265 vaccine, were the most common concerns in all race/ethnicity groups, with the ranking
266 reversed among Native Americans and Pacific Islanders. Both were chosen by more than 40% of
267 each group except Asians (38.4% [95%CI, 31.5, 45.4] lacked trust in COVID-19 vaccines). There
268 was more racial variability in not trusting the government (range: 26.2-50.0%; >40% among
269 multi-racial, White, and Native American); in waiting to see if safe (range: 27.0-42.5%; >40%
270 among Asian, Hispanic, and Black), and in do not need (range: 22.3-47.0%; >40% among multi-
271 racial and White). Other reasons were chosen by <40% of hesitant adults in each race/ethnicity
272 group.

273 **Discussion**

274 In this massive national survey of US adults, COVID-19 vaccine hesitancy decreased by one-third
275 between January and May, 2021. However, there was minimal change in the prevalence of the
276 most hesitant subgroup (those responding “definitely not”). Additionally, while a decrease in
277 hesitancy was observed across almost all categories evaluated, there was a substantial
278 difference in the magnitude of change of education and race/ethnicity categories. The largest

279 decreases were seen in the race and education categories with the highest January hesitancy
280 prevalence (e.g., Black and Pacific Islander race, ≤high school and some college education), such
281 that the disparity in hesitancy by these factors decreased. Still, May 2021 data indicates that at
282 the launch of universal vaccine eligibility, COVID-19 vaccine hesitancy varied by a wide array of
283 demographic, geographic, political and COVID-19 environment, health, belief and behavioral
284 factors. Additionally, important differences in reasons for COVID-19 vaccine hesitancy exist
285 both by degree of vaccine intent and racial/ethnic groups.

286 Racial/ethnic disparities have been observed in all aspects of the COVID-19 pandemic(30), with
287 communities of color experiencing higher rates of SARS-CoV-2 infection, as well as COVID-19-
288 related hospitalizations and mortality (31,32). Racial/ethnic disparities in COVID-19 vaccine
289 acceptance at the start of the vaccine rollout threatened to continue this trend (33), with
290 unclear/unreliable information on COVID-19 vaccines, concerns about research ethics, and
291 access barriers contributing to COVID-19 vaccine hesitancy (34). In response, groups from at-
292 risk communities initiated targeted outreach campaigns (35). The large decreases in COVID-19
293 vaccine hesitancy we measured among Blacks and Pacific Islanders, suggest that messaging and
294 outreach campaigns, combined with time to observe the initial months of the vaccine rollout,
295 had positive effects; by May 2021, Blacks and Pacific Islanders joined Asian and Hispanics in
296 having a lower prevalence of hesitancy than Whites. However, among younger adults, Blacks,
297 Native Americans, and Multi-racial groups continued to be the most hesitant. Experts continue
298 to recommend targeted campaigns to overcome structural barriers on racial and ethnic
299 disparities in COVID-19 vaccine uptake (36). Our study indicates that in May, 2021, Black and
300 Hispanic adults were more likely to be concerned about safety compared to White adults, while

301 White adults were more likely to report not trusting the government and not needing the
302 vaccine than Black and Hispanic adults.

303 January through May, there was a dose-response relationship between relative degree of local
304 Trump support in the 2020 presidential election and COVID-19 vaccine hesitancy that grew over
305 time; by May, even after controlling for potential confounders, those living in a county in the
306 top quartile were 44% more at risk of being hesitant, highlighting the politicization of public
307 health recommendations.

308 Those who were not intentionally avoiding contact with others had much higher likelihood of
309 COVID-19 vaccine hesitancy, as did those working outside the home, indicating non-vaccinated
310 individuals may be the most likely to engage in activities with transmission risk, and thus, are
311 worthy of further study and focused vaccination uptake efforts.

312 In May 2021, only 14.7% of COVID-19 vaccine hesitant respondents chose not liking vaccines as
313 a reason, indicating that COVID-19 vaccine hesitancy is likely a distinct phenomenon from
314 general vaccine hesitancy among US adults in general, as well as employed adults(9). However,
315 we also found that those who had not received a flu vaccine were 3.3 times more likely to be
316 COVID-19 vaccine hesitant, even after controlling for a wide array of covariates, which indicates
317 that efforts to increase flu vaccination uptake should address reasons of COVID-19 vaccine
318 hesitancy and vice versa.

319 Concern about side effects of COVID-19 vaccines was common across levels of vaccine intent
320 and among all racial groups. However, several reasons for COVID-19 vaccine hesitancy varied
321 substantially by subgroups. Among less hesitant (“probably not”) participants, waiting to see if

322 the vaccine is safe was a common response, suggesting messaging about safety and policy
323 interventions to address downstream impacts of vaccine side effects, such as potential lost
324 work, could be impactful. Conversely, the most hesitant (“definitely not”) participants
325 commonly reported they don’t trust the COVID-19 vaccine, don’t trust the government, and/or
326 don’t need the vaccine, suggesting the existence of a subgroup with entrenched hesitancy and
327 high distrust that may only respond to vaccine mandates.

328 **Limitations and strengths**

329 The study employs a novel sampling method with a soft ask and low response rate, the effect of
330 which has not yet been fully studied. Survey weights adjust for non-response and coverage bias
331 (i.e., matching the sample to gender, age, and geographic profile of the US). However,
332 Facebook users may differ from non-users, and our sample is more educated (37) and has
333 higher vaccine uptake(8) than the general population, indicating that we underestimated
334 vaccine hesitancy compared to the general US population. Importantly, CTIS results have been
335 consistent over time, follow similar patterns observed by others (13), and have been used to
336 track trends and inform policies (38,39).

337 Demographic questions were asked at the end of the survey and had high unit non-response
338 (e.g., 12% for age). To maximize the analysis sample and control for bias, “missing” was
339 included as a variable category; however, interpretation of estimates for this category is
340 difficult. Additionally, we assume the survey was completed in good faith. However, as noted
341 above, a small percentage of participants selected “prefer to self-describe” gender to make
342 discriminatory statements and the frequency of other characteristics in this group was suspect.

343 Thus, they were excluded from the primary analysis sample, but included in a sensitivity
344 analysis that yielded largely similar results. It is possible that additional respondents who did
345 not self-describe their gender completed the survey in bad faith.

346 A strength of our novel sampling method is that it generated a large sample with diverse
347 characteristics enabling detailed subgroup analyses that identified new findings. For example,
348 most previous studies of COVID-19 vaccine hesitancy grouped Asians with American
349 Indian/Alaska Native, Native Hawaiian or other Pacific Islanders (13,40–42). However, our
350 study, which included 11,962 Asian participants in the May sample, identified a remarkably
351 lower prevalence of hesitancy among Asians versus all other race/ethnic groups. This study also
352 identified an interaction between race/ethnicity and age (e.g., Blacks had relatively high
353 hesitancy among adults under 35 years while Whites had relatively high hesitancy among adults
354 45 and older), which have previously been reported as independent predictors of vaccine
355 hesitancy without investigating an interaction (13,43). Thus, our study provides more recent
356 and extensive data to inform race/ethnicity and age orientated COVID-19 vaccination uptake
357 efforts. Additionally, while a previous study evaluated changes in hesitancy by age, sex,
358 education, or income level, October 2020 through March 2021 (13), estimated change by these
359 categories had large overlapping 95% CI, and the racial and education categories collapsed
360 groups in which we have identified meaningful differences.

361 **Conclusion**

362 This massive national survey administered throughout the US COVID-19 vaccine rollout
363 (January-May, 2021) identified a decrease in vaccine hesitancy by one-third, with important

364 changes in hesitancy in key subgroups. This study also provided a fine-grained analysis of
365 COVID-19 vaccine hesitancy by subgroup at the time of universal vaccine availability, and
366 provided insight into reasons for hesitancy both overall and by key subgroups, revealing that
367 somewhat hesitant and strongly hesitant adults indicate different beliefs about vaccine safety.
368 These results can support the development of targeted public health campaigns and policies to
369 increase COVID-19 vaccine uptake. Additionally, as new diseases continue to emerge (44), these
370 findings can provide insight for the planning of future vaccine rollouts.

371

372 **Acknowledgements**

373 **Authors contributions**

374 Dr. Reinhart and Mr. Rubinstein had full access to all of the data and take responsibility for the
375 integrity of the data and the accuracy of the data analysis.

376 Obtained funding, supervised study and acquired data: AR

377 Developed study concept and design: WK, RM, AR

378 Performed statistical analysis: MR

379 Drafting of the manuscript: WK, RM

380 Interpreted data: WK, RM, AR, MR

381 Critically revised manuscript for important intellectual content: WK, RM, AR, MR

382 **Other acknowledgements**

383 We would like to thank the Delphi Group at Carnegie Mellon University for input and
384 support on the survey instrument. Wichada La Motte-Kerr, MPH, of Delphi contributed
385 to the development and deployment of the survey and received compensation for her
386 contributions to the study. We thank Sarah LaRocca, PhD and Katherine Morris, PhD of
387 Facebook for contributions to the survey instrument design.

388

389 **Figure Legends**

390 **Figure 1.** COVID-19 vaccine receipt and intent among US adults by month (January-May, 2021)

391 Vaccine hesitancy decreased among adults each month from January to May, mostly due to a

392 decrease in the response, “probably not” (-7.1 percentage points (%) [95% CI -7.2, -6.9]) versus

393 “definitely not” (-1.8 % [95% CI -1.9, -1.7]).

394 **Figure 2.** COVID-19 vaccine hesitancy by race/ethnicity (ages 18-34 years^a), education level, US
395 region and county Trump vote share in the 2020 presidential election among US adults by
396 month (January-May, 2021)

397 Between January and May, the gap in percent hesitant between race/ethnicity groups among
398 adults 18-34 years (panel A) and education levels among all ages (panel B) decreased, with the
399 biggest decreases among the most hesitant groups (e.g., Black race and ≤high school education,
400 respectively). Changes in percent hesitant over time were fairly similar across US regions (panel
401 C); however, there was a slightly smaller decrease in the Mountain region and slightly larger
402 decrease in the South versus other regions. The gap in percent hesitant by county political
403 environment, quantified in quartiles of percent Trump vote share in the 2020 presidential
404 election, increased slightly between January and May, with the most hesitant group (highest
405 quartile) having the smallest decrease (panel D).

406 ^a There was a significant interaction between race/ethnicity group and age group. Vaccine
407 hesitancy for all race/ethnicity groups by all age groups is provided in **sTable 6**.

408 **Figure 3.** COVID-19 vaccine hesitancy by age group, stratified by race/ethnicity, among US
409 adults, May 2021

410 Differences in hesitancy by age (e.g., 18-24 year-olds versus 65-74 year-olds) were more
411 pronounced in Blacks (RR=7.26 [95%CI, 5.92, 8.61]) versus Whites (RR=2.89 [95% CI 2.75, 3.04])
412 or other race/ethnicity groups. Asians had hesitancy <5% hesitancy in all age groups.

413 Differences in hesitancy by race/ethnicity were more pronounced in younger adults and adults
414 ≥75 years.

415 **Table 1.** COVID-19 vaccine hesitancy in May 2021 by demographics among US adults
 416 (N=525,644)

	Sample		COVID-19 vaccine hesitant		
	n	%	% (95% CI)	RR (95% CI) ^b	Adj. RR (95% CI) ^c
Gender					
Male	159427	30.3	16.6 (16.4, 16.9)	1.0 (NA)	1.0 (NA)
Female	294983	56.1	13.2 (13.1, 13.4)	0.79 (0.78, 0.81)	1.12 (1.10, 1.14)
Non-binary	3232	0.6	18.2 (16.1, 20.3)	1.10 (0.97, 1.22)	0.99 (0.88, 1.10)
No response	68002	12.9	26.3 (25.8, 26.7)	1.58 (1.54, 1.61)	1.39 (1.34, 1.44)
Age group					
18-24 years	15382	2.9	22.1 (21.3, 23.0)	2.76 (2.64, 2.88)	^d
25-34 years	52015	9.9	20.5 (20.1, 20.9)	2.56 (2.48, 2.64)	
35-44 years	72541	13.8	17.8 (17.5, 18.2)	2.22 (2.16, 2.29)	
45-54 years	81005	15.4	16.6 (16.3, 16.8)	2.07 (2.01, 2.13)	
55-64 years	102934	19.6	12.7 (12.4, 12.9)	1.58 (1.53, 1.63)	
65-74 years	95607	18.2	8.0 (7.8, 8.2)	1.0 (NA)	
≥ 75 years	41799	8.0	6.9 (6.6, 7.2)	0.86 (0.82, 0.90)	
Missing	64361	12.2	24.4 (23.9, 24.8)	3.04 (2.95, 3.13)	
Race/ethnicity^a					
White	337260	64.2	15.5 (15.4, 15.7)	1.0 (NA)	^d
Hispanic	56333	10.7	11.9 (11.5, 12.3)	0.77 (0.74, 0.79)	
Black	28546	5.4	12.9 (12.4, 13.4)	0.83 (0.79, 0.86)	
Asian	11962	2.3	2.9 (2.5, 3.3)	0.19 (0.16, 0.21)	
Native American	3944	0.8	24.9 (23.0, 26.8)	1.60 (1.48, 1.73)	
Pacific Islander	992	0.2	13.5 (10.9, 16.0)	0.87 (0.70, 1.03)	
Multi-racial	13009	2.5	26.9 (25.9, 27.9)	1.73 (1.67, 1.80)	
Missing	73598	14.0	25.9 (25.4, 26.3)	1.67 (1.63, 1.70)	
Education level					
≤ High school	91859	17.5	20.3 (20.0, 20.7)	1.89 (1.84, 1.94)	1.58 (1.54, 1.62)
Some college	166070	31.6	17.9 (17.7, 18.2)	1.67 (1.62, 1.71)	1.38 (1.35, 1.41)
4 year college	110440	21.0	10.8 (10.5, 11.0)	1.0 (NA)	1.0 (NA)
Master's	62503	11.9	7.8 (7.6, 8.1)	0.73 (0.70, 0.76)	0.88 (0.85, 0.91)
Professional (e.g., MD, JD)	14733	2.8	11.1 (10.4, 11.8)	1.03 (0.96, 1.10)	1.08 (1.02, 1.14)
Doctorate	9975	1.9	14.6 (13.5, 15.6)	1.35 (1.25, 1.45)	1.20 (1.14, 1.26)
Missing	70064	13.3	23.7 (23.3, 24.1)	2.20 (2.14, 2.27)	1.19 (1.10, 1.27)
Employment status					
Work outside home	174011	33.1	20.2 (19.9, 20.4)	2.44 (2.35, 2.53)	1.33 (1.29, 1.38)
Work at home	57015	10.8	8.3 (8.0, 8.6)	1.0 (NA)	1.0 (NA)
Does not work for pay	221728	42.2	12.4 (12.2, 12.6)	1.50 (1.44, 1.55)	1.35 (1.30, 1.40)
Missing	72890	13.9	23.6 (23.2, 24.1)	2.86 (2.75, 2.97)	1.35 (1.26, 1.43)
US Region					

Midwest	125878	23.9	17.7 (17.4, 17.9)	1.51 (1.47, 1.56)	1.10 (1.07, 1.13)
South	181704	34.6	18.8 (18.6, 19.1)	1.62 (1.56, 1.67)	1.14 (1.11, 1.17)
Pacific	72997	13.9	11.7 (11.3, 12.0)	1.0 (NA)	1.0 (NA)
Mountain	41975	8.0	17.5 (17.0, 18.0)	1.50 (1.44, 1.57)	1.12 (1.08, 1.16)
Northeast	87740	16.7	12.2 (11.9, 12.5)	1.05 (1.01, 1.09)	0.96 (0.93, 0.99)
Territories	190	0.0	10.7 (5.5, 15.9)	0.92 (0.47, 1.37)	0.64 (0.41, 0.86)
Missing	15160	2.9	29.8 (28.8, 30.7)	2.55 (2.44, 2.66)	^e
County urban classification					
Large central metro	119939	22.8	11.4 (11.2, 11.7)	1.0 (NA)	1.0 (NA)
Large fringe metro	115240	21.9	13.9 (13.6, 14.1)	1.22 (1.18, 1.25)	1.03 (1.00, 1.06)
Medium metro	137628	26.2	16.4 (16.1, 16.7)	1.44 (1.40, 1.48)	1.13 (1.10, 1.16)
Small metro	57380	10.9	20.5 (20.0, 20.9)	1.80 (1.74, 1.85)	1.18 (1.14, 1.22)
Micropolitan	48869	9.3	23.6 (23.1, 24.1)	2.07 (2.00, 2.13)	1.20 (1.16, 1.23)
Non-core	31238	5.9	26.9 (26.3, 27.6)	2.36 (2.28, 2.44)	1.23 (1.19, 1.28)
Missing	15350	2.9	29.5 (28.6, 30.5)	2.59 (2.49, 2.69)	^e

417 Juris Doctorate= JD; MD=Doctor of Medicine; NA=not applicable; NH=Non-Hispanic

418 ^a Race/ethnicity groups other than the group labeled “Hispanic” are non-Hispanic.

419 ^b A series of weighted Poisson regression models with robust error variance were used to estimate the
420 risk ratios.

421 ^c Adjusted risk ratios were estimated from a single Poisson regression model including all covariates and
422 an interaction term for age group and race/ethnicity.

423 ^d Due to an interaction between age group and race/ethnicity, adjusted relative risks from the
424 multivariable model are reported in supporting information (age group stratified by race in sTable 5;
425 race/ethnicity by age group in sTable 6).

426 ^e Reliable estimates could not be calculated for the missing category for variables based on participants’
427 zip code, due to collinearity.

428 **Table 2.** COVID-19 vaccine hesitancy in May 2021 by political/ COVID-19 environment, health
 429 status, beliefs and behaviors among US adults (N=525,644)

	Sample		COVID-19 vaccine hesitant		
	N	%	% (95% CI)	RR (95% CI) ^a	Adj. RR (95% CI) ^b
State governor's political party					
Democratic	280671	53.4	14.0 (13.8, 14.2)	1.0 (NA)	^c
Republican	228790	43.5	18.8 (18.6, 19.0)	1.34 (1.32, 1.36)	
Missing	16183	3.1	28.4 (27.4, 29.3)	2.03 (1.95, 2.10)	
County Trump vote total minus Biden vote total in 2020 presidential election					
Lowest quartile	341190	64.9	12.4 (12.3, 12.6)	1.0 (NA)	1.0 (NA)
Second lowest quartile	100974	19.2	21.4 (21.1, 21.8)	1.73 (1.69, 1.76)	1.28 (1.25, 1.30)
Second highest quartile	47061	9.0	27.0 (26.5, 27.6)	2.18 (2.12, 2.23)	1.35 (1.31, 1.38)
Highest quartile	19531	3.7	31.9 (31.1, 32.8)	2.57 (2.50, 2.65)	1.44 (1.40, 1.49)
Missing	16888	3.2	29.0 (28.1, 29.9)	2.34 (2.25, 2.42)	1.15 (1.02, 1.28)
County COVID-19 April 2021 county death rate					
Lowest quartile	25972	4.9	23.8 (23.2, 24.5)	1.0 (NA)	-
Second lowest quartile	167874	31.9	15.8 (15.5, 16.0)	0.66 (0.64, 0.68)	0.97 (0.94, 1.00)
Second highest quartile	213276	40.6	15.3 (15.1, 15.5)	0.64 (0.62, 0.66)	1.00 (0.97, 1.03)
Highest quartile	103140	19.6	16.7 (16.4, 17.0)	0.70 (0.68, 0.73)	1.01 (0.98, 1.04)
Missing	15382	2.9	29.5 (28.5, 30.5)	1.24 (1.18, 1.29)	^d
Ever tested positive for COVID-19					
Yes	55306	10.5	20.2 (19.8, 20.6)	1.26 (1.23, 1.29)	1.11 (1.09, 1.14)
No or unsure	467169	88.9	16.1 (15.9, 16.2)	1.0 (NA)	1.0 (NA)
No response	3169	0.6	17.5 (15.7, 19.2)	1.09 (0.98, 1.20)	0.91 (0.83, 0.99)
Ever diagnosed with high-risk medical condition					
One or more conditions	322188	61.3	13.3 (13.2, 13.5)	1.0 (NA)	1.0 (NA)
No conditions	182782	34.8	18.7 (18.5, 19.0)	1.41 (1.38, 1.43)	1.00 (0.99, 1.02)
Missing	20674	3.9	35.5 (34.6, 36.3)	2.66 (2.59, 2.74)	1.71 (1.66, 1.76)
Extent worried that you or someone in immediate family might become seriously ill from COVID-19					
Worried	209073	39.8	8.7 (8.6, 8.9)	1.0 (NA)	1.0 (NA)
Not too worried	164156	31.2	13.5 (13.3, 13.7)	1.55 (1.51, 1.59)	1.31 (1.28, 1.34)
Not worried at all	96414	18.3	31.9 (31.5, 32.3)	3.66 (3.58, 3.74)	1.79 (1.75, 1.83)
Missing	56001	10.7	24.7 (24.2, 25.2)	2.84 (2.76, 2.92)	1.31 (1.11, 1.52)
Lives with someone or is 65 years or older, including self					
Yes	207265	39.4	11.6 (11.4, 11.8)	1.0 (NA)	
No	203619	38.7	17.7 (17.5, 17.9)	1.53 (1.49, 1.56)	1.08 (1.05, 1.11)
No response	114760	21.8	20.9 (20.6, 21.2)	1.80 (1.76, 1.84)	1.11 (1.09, 1.14)
Past-year flu vaccine					
Yes	279745	53.2	5.5 (5.4, 5.6)	1.0 (NA)	1.0 (NA)
No or unsure	190331	36.2	27.2 (26.9, 27.5)	4.97 (4.85, 5.08)	3.27 (3.19, 3.35)
Missing	55568	10.6	24.8 (24.3, 25.3)	4.53 (4.40, 4.66)	2.11 (1.76, 2.46)
Extent intentionally avoiding contact with others					

All of the time	66728	12.7	10.8 (10.5, 11.1)	1.0 (NA)	-
Most of the time	141838	27.0	8.4 (8.2, 8.6)	0.77 (0.75, 0.80)	0.88 (0.85, 0.91)
Some of the time	186720	35.5	8.9 (8.7, 9.0)	0.82 (0.79, 0.85)	0.89 (0.86, 0.92)
None of the time	83338	15.9	42.8 (42.4, 43.3)	3.96 (3.84, 4.07)	2.45 (2.37, 2.53)
Missing	47020	8.9	26.1 (25.5, 26.6)	2.41 (2.33, 2.49)	1.46 (1.38, 1.55)

430 NA=not applicable

431 ^a A series of weighted Poisson regression models with robust error variance were used to estimate the
432 risk ratios.

433 ^b Adjusted risk ratios were estimated from a single Poisson regression model including all covariates and
434 an interaction term for age group and race/ethnicity.

435 ^c State governor's political party was excluded from the multivariable model due to collinearity with
436 county Trump vote share.

437 ^d Reliable estimates could not be calculated for the missing category for variables based on participants'
438 zip code

439

440

441 **Table 3.** Reasons for not getting the COVID-19 vaccine in May, 2021, by vaccine intent level
 442 among US adults (N=87,984)^a

	Likelihood of accepting the COVID-19 vaccine if offered it today			
	Hesitant (Definitely/ probably not)	Definitely not	Probably not	Probably yes
	N = 73362	N = 46576	N = 26786	N = 14622
	% (95% CI)			
Concerned about possible side effects	49.2 (48.7, 49.7)	49.1 (48.5, 49.7)	49.4 (48.6, 50.1)	49.4 (48.4, 50.4)
Don't trust COVID-19 vaccines	48.4 (48.0, 48.9)	59.2 (58.6, 59.8)	29.3 (28.6, 30.0)	13.0 (12.3, 13.8)
Don't trust the government	41.5 (41.1, 42.0)	51.2 (50.6, 51.7)	24.4 (23.7, 25.1)	14.0 (13.2, 14.8)
Don't believe I need it	38.1 (37.7, 38.6)	46.7 (46.1, 47.3)	22.9 (22.2, 23.5)	7.5 (6.9, 8.1)
Plan to wait and to see if safe	34.4 (33.9, 34.8)	24.3 (23.8, 24.8)	52.3 (51.5, 53.1)	46.9 (45.9, 48.0)
Concerned about an allergic reaction	23.9 (23.5, 24.3)	23.0 (22.5, 23.5)	25.6 (25.0, 26.3)	28.5 (27.5, 29.4)
Don't know if it will work	21.9 (21.5, 22.2)	23.3 (22.8, 23.8)	19.3 (18.7, 19.9)	17.0 (16.2, 17.8)
Don't like vaccines	14.7 (14.4, 15.1)	17.6 (17.1, 18.0)	9.6 (9.2, 10.1)	7.6 (7.0, 8.2)
Other people need it more	12.6 (12.3, 13.0)	9.1 (8.7, 9.5)	18.9 (18.3, 19.6)	25.1 (24.1, 26.0)
Safety concern because of my health condition	12.2 (11.9, 12.4)	11.6 (11.2, 11.9)	13.2 (12.7, 13.6)	13.4 (12.7, 14.0)
Doctor has not recommended	9.3 (9.0, 9.6)	10.1 (9.7, 10.4)	8.0 (7.6, 8.4)	6.8 (6.3, 7.3)
Against religious beliefs	8.2 (7.9, 8.5)	11.2 (10.8, 11.6)	2.9 (2.7, 3.2)	1.2 (0.9, 1.4)
Currently/planning to be pregnant/breastfeeding	6.7 (6.4, 6.9)	6.5 (6.2, 6.8)	6.9 (6.5, 7.3)	4.8 (4.4, 5.2)
Concerned about cost	3.2 (3.0, 3.4)	3.2 (2.9, 3.5)	3.3 (3.0, 3.6)	7.9 (7.3, 8.6)
Other	16.2 (15.8, 16.5)	18.6 (18.2, 19.1)	11.9 (11.4, 12.3)	11.7 (11.1, 12.4)

443 ^a Excludes adults who already were vaccinated or reported “definitely yes” to intent question.

444

445 **References**

- 446 1. Loftus P, West MG, Hopkins JS. First Covid-19 Vaccine Given to U.S. Public [Internet]. MSN.
447 [cited 2021 May 26]. Available from: [https://www.msn.com/en-us/news/us/first-covid-19-](https://www.msn.com/en-us/news/us/first-covid-19-vaccine-given-to-us-public/ar-BB1bUDkJ)
448 [vaccine-given-to-us-public/ar-BB1bUDkJ](https://www.msn.com/en-us/news/us/first-covid-19-vaccine-given-to-us-public/ar-BB1bUDkJ)

- 449 2. Hinton RDM. Pfizer-BioNTech COVID-19 Vaccine EUA Letter of Authorization reissued
450 [Internet]. 2021 [cited 2021 May 26]. Available from:
451 <https://www.fda.gov/media/144412/download>

- 452 3. Centers for Disease Control and Prevention. COVID Data Tracker [Internet]. Centers for
453 Disease Control and Prevention. 2020 [cited 2021 May 26]. Available from:
454 <https://covid.cdc.gov/covid-data-tracker>

- 455 4. Liptak K, Zeleny J, Harwood J. Biden now says US will have enough vaccine for every adult
456 by the end of May [Internet]. CNN. [cited 2021 May 26]. Available from:
457 [https://www.cnn.com/2021/03/02/politics/biden-merck-johnson--johnson-](https://www.cnn.com/2021/03/02/politics/biden-merck-johnson--johnson-vaccine/index.html)
458 [vaccine/index.html](https://www.cnn.com/2021/03/02/politics/biden-merck-johnson--johnson-vaccine/index.html)

- 459 5. Office of the Commissioner. Pfizer-BioNTech COVID-19 Vaccine. FDA [Internet]. 2021 Jun
460 11 [cited 2021 Jun 25]; Available from: [https://www.fda.gov/emergency-preparedness-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine)
461 [and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine)

- 462 6. Rearden C. Gov. Wolf announces effort to get COVID-19 vaccines to homebound
463 individuals [Internet]. WFMZ.com. [cited 2021 May 26]. Available from:
464 [https://www.wfmz.com/health/coronavirus/gov-wolf-announces-effort-to-get-covid-19-](https://www.wfmz.com/health/coronavirus/gov-wolf-announces-effort-to-get-covid-19-vaccines-to-homebound-individuals/article_f13537dc-a6d6-11eb-a00c-5f21dab164af.html)
465 [vaccines-to-homebound-individuals/article_f13537dc-a6d6-11eb-a00c-5f21dab164af.html](https://www.wfmz.com/health/coronavirus/gov-wolf-announces-effort-to-get-covid-19-vaccines-to-homebound-individuals/article_f13537dc-a6d6-11eb-a00c-5f21dab164af.html)

- 466 7. Pietsch B. Dracula’s Castle Is Now a Vaccination Site - The New York Times [Internet]. 2021
467 [cited 2021 Jun 25]. Available from: [https://www.nytimes.com/2021/05/12/us/covid-](https://www.nytimes.com/2021/05/12/us/covid-vaccine-unusual-location.html)
468 [vaccine-unusual-location.html](https://www.nytimes.com/2021/05/12/us/covid-vaccine-unusual-location.html)

- 469 8. CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. 2020
470 [cited 2021 Aug 1]. Available from: <https://covid.cdc.gov/covid-data-tracker>

- 471 9. King WC, Rubinstein M, Reinhart A, Mejia R. COVID-19 vaccine hesitancy January-May
472 2021 among 18–64 year old US adults by employment and occupation. Preventive
473 Medicine Reports. 2021 Dec 1;24:101569.

- 474 10. Bosman J, Hoffman J, Sanger-Katz M, Arango T. Who Are the Unvaccinated in America?
475 There’s No One Answer. The New York Times [Internet]. 2021 Jul 31 [cited 2021 Aug 1];
476 Available from: [https://www.nytimes.com/2021/07/31/us/virus-unvaccinated-](https://www.nytimes.com/2021/07/31/us/virus-unvaccinated-americans.html)
477 [americans.html](https://www.nytimes.com/2021/07/31/us/virus-unvaccinated-americans.html)

- 478 11. Sun A, Heyward G. American Hospitals Buckle Under Delta, With I.C.U.s Filling Up. The
479 New York Times [Internet]. 2021 Aug 17 [cited 2021 Aug 19]; Available from:
480 <https://www.nytimes.com/interactive/2021/08/17/us/covid-delta-hospitalizations.html>
- 481 12. Hernandez J. Alabama Hospitals Have Run Out Of ICU Beds As COVID-19 Cases Surge. NPR
482 [Internet]. 2021 Aug 19 [cited 2021 Aug 19]; Available from:
483 <https://www.npr.org/2021/08/19/1029260134/alabama-hospitals-icu-beds>
- 484 13. Daly M, Jones A, Robinson E. Public Trust and Willingness to Vaccinate Against COVID-19 in
485 the US From October 14, 2020, to March 29, 2021. JAMA. 2021 Jun 15;325(23):2397.
- 486 14. Salomon JA, Reinhart A, Bilinski A, Chua EJ, Motte-Kerr WL, Rönn MM, et al. The U.S.
487 COVID-19 Trends and Impact Survey, 2020-2021: Continuous real-time measurement of
488 COVID-19 symptoms, risks, protective behaviors, testing and vaccination. Proceedings of
489 the National Academy of Sciences. 2021;in press.
- 490 15. Barkay N, Cobb C, Eilat R, Galili T, Haimovich D, LaRocca S, et al. Weights and Methodology
491 Brief for the COVID-19 Symptom Survey by University of Maryland and Carnegie Mellon
492 University, in Partnership with Facebook. arXiv:200914675 [cs] [Internet]. 2020 Oct 6
493 [cited 2021 May 26]; Available from: <http://arxiv.org/abs/2009.14675>
- 494 16. Baack BN. COVID-19 Vaccination Coverage and Intent Among Adults Aged 18–39 Years —
495 United States, March–May 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited
496 2021 Aug 2];70. Available from:
497 <https://www.cdc.gov/mmwr/volumes/70/wr/mm7025e2.htm>
- 498 17. US Census Bureau. Race/Ethnicity and the 2020 Census [Internet]. Census 20/20. [cited
499 2021 Aug 2]. Available from: [https://www.census2020now.org/faces-blog/same-sex-](https://www.census2020now.org/faces-blog/same-sex-households-2020-census-r3976)
500 [households-2020-census-r3976](https://www.census2020now.org/faces-blog/same-sex-households-2020-census-r3976)
- 501 18. American Community Survey. Census - Table Results [Internet]. [cited 2021 Aug 2].
502 Available from: [https://data.census.gov/cedsci/table?d=ACS%201-](https://data.census.gov/cedsci/table?d=ACS%201-Year%20Estimates%20Data%20Profiles&tid=ACSDP1Y2019.DP05)
503 [Year%20Estimates%20Data%20Profiles&tid=ACSDP1Y2019.DP05](https://data.census.gov/cedsci/table?d=ACS%201-Year%20Estimates%20Data%20Profiles&tid=ACSDP1Y2019.DP05)
- 504 19. US Census Bureau. Educational Attainment [Internet]. The United States Census Bureau.
505 [cited 2021 Aug 12]. Available from:
506 <https://www.census.gov/topics/education/educational-attainment/about.html>
- 507 20. US Census Bureau. Geographic Areas Reference Manual (Ch.6) [Internet]. The United
508 States Census Bureau. [cited 2021 Jun 25]. Available from:
509 [https://www.census.gov/programs-surveys/geography/guidance/geographic-areas-](https://www.census.gov/programs-surveys/geography/guidance/geographic-areas-reference-manual.html)
510 [reference-manual.html](https://www.census.gov/programs-surveys/geography/guidance/geographic-areas-reference-manual.html)
- 511 21. CDC. COVID Data Tracker (Vaccination) [Internet]. Centers for Disease Control and
512 Prevention. 2020 [cited 2021 Oct 17]. Available from: [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker)
513 [tracker](https://covid.cdc.gov/covid-data-tracker)

- 514 22. Centers for Disease Control and Prevention. Data Access - Urban Rural Classification
515 Scheme for Counties [Internet]. 2019 [cited 2021 Jun 25]. Available from:
516 https://www.cdc.gov/nchs/data_access/urban_rural.htm
- 517 23. JHU Cases and Deaths [Internet]. Delphi Epidata API. [cited 2021 Jun 25]. Available from:
518 <https://cmu-delphi.github.io/delphi-epidata/api/covidcast-signals/jhu-csse.html>
- 519 24. New York Times. Data file [Internet]. [cited 2021 Jun 27]. Available from:
520 [https://static01.nyt.com/elections-assets/2020/data/api/2020-11-03/national-map-](https://static01.nyt.com/elections-assets/2020/data/api/2020-11-03/national-map-page/national/president.json)
521 [page/national/president.json](https://static01.nyt.com/elections-assets/2020/data/api/2020-11-03/national-map-page/national/president.json)
- 522 25. Partisan composition of governors [Internet]. Ballotpedia. [cited 2021 Jun 25]. Available
523 from: https://ballotpedia.org/Partisan_composition_of_governors
- 524 26. Centers for Disease Control and Prevention. Underlying Medical Conditions Associated
525 with High Risk for Severe COVID-19: Information for Healthcare Providers [Internet].
526 Centers for Disease Control and Prevention. 2020 [cited 2021 May 26]. Available from:
527 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>
- 528 27. Zou G. A modified poisson regression approach to prospective studies with binary data.
529 *Am J Epidemiol.* 2004 Apr 1;159(7):702–6.
- 530 28. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an
531 empirical comparison of models that directly estimate the prevalence ratio. *BMC Medical*
532 *Research Methodology.* 2003 Oct 20;3(1):21.
- 533 29. Freedman DA. On The So-Called “Huber Sandwich Estimator” and “Robust Standard
534 Errors.” *The American Statistician.* 2006 Nov 1;60(4):299–302.
- 535 30. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 — A Dangerous
536 Convergence for Black Americans. *N Engl J Med.* 2020 Sep 17;383(12):e77.
- 537 31. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, et al. Patterns of
538 COVID-19 testing and mortality by race and ethnicity among United States veterans:
539 A nationwide cohort study. *PLoS Med.* 2020 Sep;17(9):e1003379.
- 540 32. Gu T, Mack JA, Salvatore M, Prabhu Sankar S, Valley TS, Singh K, et al. Characteristics
541 Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health
542 Care System. *JAMA Netw Open.* 2020 Oct 21;3(10):e2025197.
- 543 33. Jimenez ME, Rivera-Núñez Z, Crabtree BF, Hill D, Pellerano MB, Devance D, et al. Black and
544 Latinx Community Perspectives on COVID-19 Mitigation Behaviors, Testing, and Vaccines.
545 *JAMA Netw Open.* 2021 Jul 15;4(7):e2117074.

- 546 34. Carson SL, Casillas A, Castellon-Lopez Y, Mansfield LN, Morris D, Barron J, et al. COVID-19
547 Vaccine Decision-making Factors in Racial and Ethnic Minority Communities in Los
548 Angeles, California. *JAMA Network Open*. 2021 Sep 30;4(9):e2127582.
- 549 35. Lopez-Villafana A. Black nurses bring vaccine to community centers, churches to target
550 under-served people [Internet]. *San Diego Union-Tribune*. 2021 [cited 2021 Jun 25].
551 Available from: [https://www.sandiegouniontribune.com/communities/san-](https://www.sandiegouniontribune.com/communities/san-diego/story/2021-03-17/san-diegos-black-nurses-focus-on-vaccinating-black-residents-in-southeastern-san-diego)
552 [diego/story/2021-03-17/san-diegos-black-nurses-focus-on-vaccinating-black-residents-in-](https://www.sandiegouniontribune.com/communities/san-diego/story/2021-03-17/san-diegos-black-nurses-focus-on-vaccinating-black-residents-in-southeastern-san-diego)
553 [southeastern-san-diego](https://www.sandiegouniontribune.com/communities/san-diego/story/2021-03-17/san-diegos-black-nurses-focus-on-vaccinating-black-residents-in-southeastern-san-diego)
- 554 36. Njoku A, Joseph M, Felix R. Changing the Narrative: Structural Barriers and Racial and
555 Ethnic Inequities in COVID-19 Vaccination. *International Journal of Environmental*
556 *Research and Public Health*. 2021 Jan;18(18):9904.
- 557 37. US Census Bureau. American Community Survey 5-Year Data (2009-2019) [Internet]. The
558 United States Census Bureau. [cited 2021 Jun 27]. Available from:
559 <https://www.census.gov/data/developers/data-sets/acs-5year.html>
- 560 38. Lessler J, Grabowski MK, Grantz KH, Badillo-Goicoechea E, Metcalf CJE, Lupton-Smith C, et
561 al. Household COVID-19 risk and in-person schooling. *Science*. 2021 Jun
562 4;372(6546):1092–7.
- 563 39. Institute for Health Metrics and Evaluation. IHME | COVID-19 Projections [Internet].
564 Institute for Health Metrics and Evaluation. [cited 2021 Jul 9]. Available from:
565 <https://covid19.healthdata.org/>
- 566 40. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes Toward a
567 Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults. *Ann Intern Med*. 2020 Dec
568 15;173(12):964–73.
- 569 41. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the
570 United States: How many people would get vaccinated? *Vaccine*. 2020 Sep
571 29;38(42):6500–7.
- 572 42. Head KJ, Kasting ML, Sturm LA, Hartsock JA, Zimet GD. A National Survey Assessing SARS-
573 CoV-2 Vaccination Intentions: Implications for Future Public Health Communication
574 Efforts. *Science Communication*. 2020 Oct;42(5):698–723.
- 575 43. Szilagyi PG, Thomas K, Shah MD, Vizueta N, Cui Y, Vangala S, et al. National Trends in the
576 US Public’s Likelihood of Getting a COVID-19 Vaccine—April 1 to December 8, 2020. *JAMA*.
577 2021 Jan 26;325(4):396.
- 578 44. Morens DM, Fauci AS. Emerging Pandemic Diseases: How We Got to COVID-19. *Cell*. 2020
579 Sep 3;182(5):1077–92.

580

581 **Supporting Information**

582 **sAppendix.** Carnegie Mellon University (CMU) Delphi Group's COVID Trends and Impact Survey (CTIS):
583 select questions and response sets.

584 **sTable 1.** Participant flow for Carnegie Mellon University (CMU) Delphi Group's COVID Trends and
585 Impact Survey (CTIS) by month (January-May, 2021)

586 **sTable 2.** Weighted demographics of the report sample by month. The distribution of responses is
587 provided including and excluding missing responses for each item.

588 **sTable 3.** COVID-19 vaccine receipt and intent by month (January-May, 2021), among US adults

589 **sTable 4.** COVID-19 vaccine hesitancy by race/ethnicity, education level, US region and county Trump
590 vote share in the 2020 presidential election, respectively, by month (January-May, 2021), among US
591 adults

592 **sTable 5.** COVID-19 vaccine hesitancy in May 2021 by age groups, stratified by race/ethnicity^a among US
593 adults

594 **sTable 6.** COVID-19 vaccine hesitancy in May 2021 by race/ethnicity^a, stratified by age groups, among
595 US adults

596 **sTable 7.** COVID-19 vaccine hesitancy in May 2021 by health condition and status^a among US adults


597 **sTable 8.** Sensitivity analysis: COVID-19 vaccine hesitancy in May 2021 by demographics among US
598 adults, including those that self-described gender (N=529,658)

599 **sTable 9.** Sensitivity analysis: COVID-19 vaccine hesitancy in May 2021 political/by COVID-19
600 environment, health status, beliefs and behaviors among US adults, including those that self-described
601 gender (N=529,658)

602 **sTable 10.** Reasons for COVID-19 vaccine hesitancy in May 21 by race/ethnicity^a among hesitant US
603 adults (N=73362)^b

604


Vaccine intent (%; 95% CI error bars)




Would you take the COVID-19 vaccine if offered today?

- Already vaccinated
- Yes, definitely
- Yes, probably
- No, probably not
- No, definitely not


A




B



C



D



Race/ethnicity

White

Hispanic

Black


Asian

Native American

Pacific Islander

75 or more years
65-74 years
55-64 years
45-54 years
35-44 years
25-34 years
18-24 years

75 or more years
65-74 years
55-64 years
45-54 years
35-44 years
25-34 years
18-24 years



0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50

Vaccine hesitant (%; 95% CI error bars)